AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata

Evommune reports Phase 2b trial miss for EVO756 in chronic spontaneous urticaria

AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo

NeuroSense reports Phase 2 proof-of-concept study results for PrimeC in Alzheimer's Disease

Vascarta announces VAS-101 Phase I results in sickle cell disease patients

Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes

Kither Biotech completes Phase 1 KIT2014 clinical study

Gesynta Pharma reports progress in Phase 2 trial of vipoglanstat

Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease

Halia Therapeutics' ofirnoflast granted FDA Fast Track designation for lower-risk myelodysplastic syndromes

Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19

Sanofi halts phase 3 MOBILIZE study of riliprubart in CIDP

Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial

FDA grants rare paediatric disease designation to RedHill's opaganib

Antengene presents first ATG-207 preclinical data at EULAR 2026